Figure 3.
Freedom from progression (FFP). Kaplan–Meier curves for freedom from progression, stratified by diagnostic CIP2A level for (a) all 172 patients, (b) imatinib recipients, and (c) dasatinib recipients. p-values were determined using the log-rank (Mantel–Cox) test; p-values are shown where significant.
